US Patent Issued to ALGERNON PHARMACEUTICALS on April 22 for "Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease" (Canadian Inventor)

ALEXANDRIA, Va., June 6 -- United States Patent no. 12,280,026, issued on April 22, was assigned to ALGERNON PHARMACEUTICALS INC. (Vancouver, Canada).

"Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease" was invented by Mark Williams (Winnipeg, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefylline are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject."

The patent was filed on June 25, 2019, under Application No. 17/255,364.

*For further information, including images, charts and tables, pleas...